Generic Name and Formulations:
Guanfacine (as HCl) 1mg, 2mg, 3mg, 4mg; ext-rel tabs.
Shire US, Inc.
Indications for INTUNIV:
Attention deficit hyperactivity disorder (ADHD), as monotherapy or as an adjunct to stimulant medications.
≥18yrs: not established.
Swallow whole with water, milk, or other liquid. Do not give with high-fat meals. <6yrs: not established. 6–17yrs: Initially 1mg once daily; adjust in increments of no more than 1mg/week; target range: 0.05–0.12mg/kg/day (1–7mg/day). Doses >4mg/day: not evaluated in children (6–12yrs); doses >7mg/day: not evaluated in adolescents (13–17yrs). Reevaluate periodically. Withdraw gradually (by 1mg every 3–7 days). Dose adjustment with concomitant strong and moderate CYP3A4 inhibitors or inducers: see full labeling.
Concomitant use with other forms of guanfacine.
Do not substitute with other forms of guanfacine on a mg-mg basis. Concomitant antihypertensives, other risks for hypotension, syncope, bradycardia, heart block, cardiovascular or cerebrovascular disease. Monitor heart rate, BP. Dehydration. Elevated temperature. Cardiac conduction abnormalities. Avoid abrupt discontinuation to minimize risk of rebound hypertension. Renal or hepatic impairment. Pregnancy (Cat.B). Nursing mothers.
Central alpha-2A agonist.
Avoid with alcohol. May be potentiated by strong and moderate CYP3A4 inhibitors (eg, ketoconazole, fluconazole). May be antagonized by strong and moderate CYP3A4 inducers (eg, carbamazepine, rifampin, efavirenz). Additive effects with other antihypertensives, CNS depressants (eg, benzodiazepines, antipsychotics, barbiturates). May worsen sinus node dysfunction and AV block when concomitant other sympatholytic drugs; monitor.
Somnolence, sedation, fatigue, nausea, lethargy, hypotension, insomnia, dizziness, abdominal pain, dry mouth, vomiting, irritability, constipation; bradycardia, hypertensive encephalopathy.
Clinical Pain Advisor Articles
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Stat Consult: Chronic Low Back Pain
- Opioid Misuse May Help Predict Alcohol Dependence Treatment Outcomes
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- OnabotulinumtoxinA May Be Effective for Chronic Migraine With Medication Overuse
- FDA Outlines Plan for Increasing Nonprescription Drug Availability
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Hypoesthesia for Touch and Joint Position Linked to Chronic Pain in MS
- New Laws Are Needed to Protect Health Data Shared Online